⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRMD News
CorMedix Inc.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
globenewswire.com
CRMD
CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
prnewswire.com
CRMD
Form 8-K
sec.gov
CRMD
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
CRMD
Quantum Health Showcases Continued Innovation that Lowers the Total Cost of Care
businesswire.com
CRMD
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
globenewswire.com
CRMD
Mundipharma gibt positive vorläufige Ergebnisse der Phase-III-Studie ReSPECT bekannt, in der ▼ REZZAYO ® (Rezafungin) zur Prophylaxe invasiver Pilzerkrankungen nach einer allogenen hämatopoetischen Stammzelltransplantation untersucht wurde
businesswire.com
CRMD
Mundipharma宣布评估用于预防异基因造血干细胞移植患者侵袭性真菌病的 ▼ REZZAYO ® （雷扎芬净）的三期ReSPECT临床试验取得积极总体结果
businesswire.com
CRMD
Mundipharma anuncia resultados positivos preliminares del estudio de Fase III ReSPECT que evalúa ▼ REZZAYO ® (rezafungina) para la profilaxis de enfermedades fúngicas invasivas en pacientes sometidos a trasplante...
businesswire.com
CRMD
Mundipharma annonce les premiers résultats positifs de l’essai de phase III ReSPECT évaluant ▼ REZZAYO ® (rézafungine) dans la prophylaxie des infections fongiques invasives chez les patients ayant subi une greffe allogénique...
businesswire.com
CRMD